Read about the latest developments in RECOVER
REMAP-CAP, an Adaptive Platform Trial for Community-Acquired Pneumonia, launched its second in a series of videos. The video shows the uniqueness, smart, and easy-to-handle design of this trial. As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment.
PRESS RELEASE: International Trial of SARS-CoV-2 Convalescent Plasma Pauses Enrollment of Critically Ill COVID-19 Patients
This decision based on an initial analysis of all severely ill COVID-19 trial participants requiring intensive care unit (ICU) support. This analysis showed that convalescent plasma did not improve outcomes in this group. There was no evidence of harm associated with the administration of convalescent plasma.
Initial findings reported in November showed that tocilizumab, a drug used to treat arthritis, was likely to improve outcomes among critically ill COVID-19 patients. But the impact on patient survival and length of time on organ support in ICU was not clear at that time.
Now, the latest analysis shows that tocilizumab and a second drug called sarilumab – both types of immune modulators called IL-6 receptor antagonists – have a significant impact on patient survival, reducing mortality by 8.5%.
The experience of European hospital-based health care workers on following infection prevention and control procedures for COVID-19
Working under pandemic conditions exposes health care workers (HCWs) to infection risk and psychological strain. Protecting the physical and psychological health of HCWs is a key priority. The Social Sciences team of RECOVER assessed the perceptions of European hospital HCWs of local infection prevention and control (IPC) procedures during the COVID-19 pandemic and the impact on their emotional wellbeing.
Critically ill patients with COVID-19 treated with a drug that reduces inflammation by modifying the immune system require shorter durations of organ support in the intensive care unit, an international study has found.
REMAP-CAP, an Adaptive Platform Trial for Community-Acquired Pneumonia, launched its first in a series of videos. The video shows the uniqueness, smart, and easy-to-handle design of this trial. As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment.
Our research presents an in-depth analysis of data from drive through testing stations using rapid antigen detection tests, to assess their ability of to detect infectious cases. We show that the detection limits of five commercially available tests differ considerably, impacting the translation into the detection of infectious cases.
The European Commission has launched a manifesto to maximise the accessibility of research results in the fight against COVID-19. It provides guiding principles for beneficiaries of EU research grants for coronavirus prevention, testing, treatment and vaccination to ensure that their research results will be accessible for all and guarantee a return on public investment.
RECOVER Consortium Member, Dr. Christian Drosten, was awarded the Federal Cross of Merit (Bundesverdienstkreuz) for his contribution to the COVID-19 pandemic. The Federal Cross of Merit is the highest federal decoration of Germany, awarded by the Order of Merit of the Federal Republic of Germany.
On 19 August 2020 the Social Sciences team of RECOVER co-authored an article in the BMJ arguing that face coverings should be considered a social practice rather than medical equipment.